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Abstract: 45 
 46 
Objective: Autoimmune polyendocrine syndrome type 1 (APS 1) is caused by mutations in the AIRE 47 
gene that induce intrathymicT-cell tolerance breakdown, which results in tissue-specific autoimmune 48 
diseases. Design: To evaluate the effect of a well-defined T-cell repertoire impairment on humoral 49 
self-reactive fingerprints, comparative serum self-IgG and -IgM reactivities were analyzed using both 50 
one- and two-dimensional western blotting approaches against a broad spectrum of peripheral tissue 51 
antigens. Methods: Autoantibody patterns of APS 1 patients were compared with those of subjects 52 
affected by other autoimmune endocrinopathies (OAE) and healthy controls. Results: Using a Chi-53 
square test, significant changes in the Ab repertoire were found when intergroup patterns were 54 
compared. A singular distortion of both serum self-IgG and self-IgM repertoires was noted in APS 1 55 
patients. The molecular characterization of these antigenic targets was conducted using a proteomic 56 
approach. In this context, autoantibodies recognized more significantly either tissue-specific antigens, 57 
such as pancreatic amylase, pancreatic triacylglycerol lipase and pancreatic regenerating protein 1, or 58 
widely distributed antigens, such as peroxiredoxin-2, heat shock cognate 71-kDa protein and aldose 59 
reductase. As expected, a well-defined self-reactive T-cell repertoire impairment, as described in APS 60 
1 patients, affected the tissue-specific self-IgG repertoire. Interestingly, discriminant IgM reactivities 61 
targeting both tissue-specific and more widely expressed antigens were also specifically observed in 62 
APS 1 patients. Using recombinant targets, we observed that post translational modifications of these 63 
specific antigens impacted upon their recognition. Conclusions: The data suggest that T-cell-64 
dependent but also T-cell-independent mechanisms are involved in the dynamic evolution of 65 
autoimmunity in APS 1. 66 
67 
Introduction 68 
Autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; OMIM ID: 69 
601240; 240300), also known as “Autoimmune Polyendocrine Syndrome type 1” (APS 1), is a rare 70 
monogenic autosomal recessive disease associated with autoimmune regulator (AIRE) gene mutations 71 
(1, 2). The AIRE gene is located on chromosome 21(21q22.3) and encodes the Aire protein, which is 72 
expressed in thymic medullary epithelial cells (mTECs), but also in dendritic cells and monocytes (1) 73 
in spleen and lymph nodes (3). Aire expresses many structural and functional characteristics common 74 
to transcriptional regulators (4). Experimental models using Aire
–/– 
animals have shown that Aire is 75 
involved in intrathymicT-cell-negative selection because it promotes ectopic expression of a subset of 76 
peripheral tissue-specific antigens (TS-Ags) by mTECs (5, 6). Loss of Aire-dependent thymic 77 
expression of a peripheral TS-Ag (such as mucin-6) results in autoimmune reactivity against this 78 
protein (7). Aire is also expressed in extra-thymic Aire-expressing cells (eTACs), like myeloid and 79 
lymphoid cells (8), in lymph nodes and spleen, where it regulates a set of TS-Ags, suggesting that Aire 80 
expression has broad transcriptional consequences for TS-Ag presentation in the periphery. 81 
Interestingly, the genes regulated by AIRE in eTACs had no overlap with AIRE-regulated genes in the 82 
thymus, suggesting a complementary role in the maintenance of self-tolerance (3). Aire
–/–
 mice 83 
develop tissue-specific autoantibodies (autoAbs) and lymphocyte infiltrates in multiple organs (5, 6). 84 
In humans, APS 1 is characterized by several tissue-specific autoimmune diseases (9) associated with 85 
organ-specific but also non-organ-specific autoAbs detected in the serum (10). Antibodies against 86 
cytokines have also been reported (11, 12). APS 1 patients develop endocrine autoimmune diseases, 87 
such as adrenal insufficiency, hypoparathyroidism, hypogonadism, type 1 diabetes mellitus and 88 
Hashimoto thyroiditis, and non-endocrine autoimmune diseases, such as pernicious anemia, hepatitis, 89 
alopecia, vitiligo and candidiasis (9). Thus, APS 1 represents a unique monogenic human model in 90 
which a well-demonstrated T-cell tolerance breakdown occurs that can result in several tissue-specific 91 
autoimmune diseases. Although numerous APS 1tissue-specific target antigens have been described, 92 
the global systemic self-antibody repertoire remains to be defined. We have previously performed 93 
such a global immunoproteomic approach in healthy subjects and in patients with different 94 
autoimmune diseases (13–15). In healthy subjects, the human Ab repertoire is thought to be well 95 
conserved and restricted to a few self-antigens in homologous tissues (16). Nevertheless, in each 96 
subject, singular patterns were found, possibly related to individual responses against exoantigens 97 
(13). Interestingly, a distortion of serum self-IgG patterns in organ-specific autoimmune diseases that 98 
predominantly involve T cells, such as multiple sclerosis, has been demonstrated in our laboratory 99 
(13). The intriguing aspect of these data was that discriminant reactivities were supported by widely 100 
distributed antigens (14). To define more precisely the pathophysiological significance of these 101 
fingerprints, we evaluated, in the present study, the autoreactive antibody response in a pathology 102 
where well-defined molecular defects, related to tolerance induction processes, have been described. 103 
To evaluate T-cell-dependent and T-cell-independent involvement in APS 1, we compared self 104 
immunological patterns obtained with both IgG and IgM autoAbs and characterized the respective 105 
molecular targets recognized.  106 
 107 
Subjects and Methods 108 
Patients 109 
Sera from 48 patients were analyzed. The samples were obtained from 14 patients with APS 1 110 
(group 1: 9 males, 5 females, mean age = 33 ± 14 years), 17 patients with other autoimmune 111 
endocrinopathies (OAE) (group 2: 6 males, 11 females, mean age = 47. 6 ± 15.1 years) and 17 healthy 112 
controls (group 3: 9 females, 8 males, mean age = 33.1 ± 9.2 years). APS 1 patients were clinically 113 
diagnosed according to Neufeld criteria (17) and confirmed by DNA sequencing as described 114 
previously (18). OAE patients presented either single or multiple endocrinopathy (Table 1). Sera were 115 
collected with the subjects’ written consent and the study was approved by the local ethics committee.  116 
 117 
Anti-cytokine ELISA 118 
 Serum reactivities towards interleukin (IL)-22, IL-17A, IL-17F, IFN-omega and IFN-alpha2A 119 
(all from R and D Systems, Minneapolis, MN), were evaluated in both APS 1 and OAE patients using 120 
ELISAs, as previously reported (12), with either anti-human IgG or IgM alkaline phosphatase-121 
conjugate (Sigma-Aldrich, Poole, UK) as the secondary antibody.  122 
 123 
Tissues 124 
Tissue samples were extracted from post-operative fragments with the patients’ written 125 
consent or from post-mortem samples. Adrenal tissue was obtained from adrenalectomies performed 126 
during nephrectomies for kidney adenocarcinoma; none of the adrenal tissues had been invaded by 127 
tumors. Pancreas samples were obtained during postmortem dissections within 6 hours of death and 128 
were performed with the approval of the local ethics committee.  129 
 130 
Western blotting and related analytical procedures 131 
One-dimensional electrophoresis (1-DE) or two-dimensional electrophoresis (2-DE) was 132 
performed as described in (14). For immunostaining, the gels were blotted onto Hybond-P PVDF 133 
membranes (Amersham Pharmacia Biotech Europe GmbH, Saclay, France) using a semidry protocol 134 
(8 mA per cm²) as in (14). Dilution of secondary antibodies coupled to peroxidase was1/5000 for anti-135 
human Fc and 1/10000 for anti-human Fcantibodies. Superimposition and alignment of antibody 136 
reactivity was performed using Diversity Database Fingerprint software (version 22; BioRad, 137 
Hercules, CA, USA) for 1-DE and PDQuest software (BioRad) for 2-DE.  138 
 139 
Two-dimensional electrophoresis (2-DE) 140 
Tissue homogenization and 1-DE protein separation were done as previously described (11). 141 
Briefly, 100 mg of each tissue was homogenized in a detergent solution (4% Triton X100, 1X anti-142 
protease cocktail; Sigma, St Louis, MO, USA) and ground using a grinding kit (GE Healthcare) before 143 
protein precipitation with a 2D cleanup kit (GE Healthcare). The supernatant was removed and the 144 
pellet was resuspended in 250 ml of sample buffer (8 M urea/2 M thiourea [Sigma], 4% CHAPS 145 
[Sigma]). Protein concentration was determined using the Bradford assay (BioRad). Proteins (500 mg 146 
per gel) were eluted into rehydration buffer (8 M urea/2 M thiourea [Sigma], 2% CHAPS [Sigma], 147 
DeStreak reagent [15 mg/ml, GE Healthcare] and ampholytes [1% IPG buffer, GE Healthcare]) before 148 
first separation according to their isoelectric points along a nonlinear immobilized pH-gradient (IPG) 149 
strip (pH 3–11 NL, 18 cm long) using an IPGphor III apparatus (GE Healthcare), as described 150 
elsewhere (14). For the second dimension, equilibrated strips were loaded onto 8–18% SDS-151 
polyacrylamide gels and electrophoresis was performed as in (19). One preparative gel was stained 152 
with CBB G-250 (Sigma) and used for spot cutting and protein sequencing. The remaining gels were 153 
electroblotted onto ECL membranes (GE Healthcare).  154 
 155 
In-gel digestion and MALDI-TOF/TOF MS analysis 156 
Protein identification was performed using a Proteineer
TM
 workflow from BrukerDaltonics 157 
(Bremen, Germany). Colloidal Coomassie blue-stained spots were excised from preparative 2D gels 158 
using a spot picker (PROTEINEER sp™) and placed onto 96-well microtiter plates. In-gel digestion 159 
and sample preparation for MALDI-TOF/TOF analysis were performed according to the 160 
manufacturer’s instructions using a digester/spotter robot (PROTEINEER dp™) and a digestion kit 161 
(DP 96 standard kit, BrukerDaltonics). The MALDI target plate (AnchorChip™, BrukerDaltonics) 162 
was covered with a cyanohydroxycinnamic acid (CHCA) matrix (0.3 mg/ml in acetone:ethanol, 3:6 163 
v/v). Extracted peptides were applied directly onto the CHCA matrix thin layer. The molecular mass 164 
measurements were performed in automatic mode using FlexControl™ 22 software on an Ultraflex™ 165 
TOF/TOF instrument (BrukerDaltonics), in the reflection mode for the MALDI-TOF peptide mass 166 
fingerprint (PMF) and in LIFT mode for the MALDI-TOF/TOF peptide fragmentation fingerprint 167 
(PFF). External calibration was performed using a peptide calibration standard kit (BrukerDaltonics). 168 
Peak lists were generated from MS and MS/MS spectra using Flexanalysis™ 24 software 169 
(BrukerDaltonics). Database searches using Mascot (Matrix Science Ltd, London, UK) and PMF 170 
datasets were performed via ProteinScape 13 (BrukerDaltonics). Searches were conducted for 171 
monoisotopic peptide masses using the NCBI and Swiss-Prot protein databases and Mascot 172 
(www.matrix-science.com). Various parameters were used for database searches: mammal species, 173 
one missed cleavage, chemical partial modifications (oxidation of methionines, cysteines modified by 174 
carbamidomethylation) and a mass tolerance of 75 ppm and 0.5 Da for fragment ions. Criteria used to 175 
accept the identifications included the probability score and the number of matched peptides 176 
(minimum of 6 peptides).  177 
 178 
Recombinant proteins 179 
GST-tagged full length recombinant proteins were purchased from ABNOVA (Aachen, 180 
Germany): pancreatic amylase (AMY2A, AAH07060); pancreatic triacylglycerol lipase (PNLIP, 181 
AAH14309.1); pancreatic regenerating protein 1 (REG1A, AAH05350); aldose reductase 182 
(AKR1B1AAH00260); peroxiredoxin 2 (PRDX2, AAH00452.1); heat shock cognate 71-kDa protein 183 
(HSPA8, AAH16179). They were all produced in wheat germ cell-free system. Five micrograms were 184 
loaded on SDS-PAGE mini-gels (Biorad), and were processed as described earlier in the western 185 
blotting procedure.  186 
 187 
Statistical analysis 188 
Data were expressed in binary mode (0 = absence of an antigenic band; 1 = presence of an 189 
antigenic band) to analyze IgG and IgM antibody patterns using the Chi-square test (a p value “P”< 190 
5.10
-2
 was judged as significant). This approach enabled us to select antigens indicative of 191 
qualitatively different immune recognition among the 3 groups, within groups 1 and 2 and within 192 
groups 1 and 3.  193 
 194 
Results 195 
Validation of serum and western blotting procedure 196 
Anti-cytokine antibody reactivity (anti-IFN alpha2A, IFN-omega, anti IFN-lambda1, anti-IL-197 
17A anti-IL-17F, and anti-IL-22) was -evaluated in APS 1 and OAE patients, in order to qualify the 198 
sera of the 2 groups (Supplemental Table 1). IgM anti-cytokine reactivity and IgG anti-IL-17A were 199 
never observed neither in OAE, nor in APS-1 patients. By contrast, IgG anti-IFN-alpha2A, anti-IFN-200 
omega, anti-IL22 and anti-IL-17F were predominantly observed in APS 1 compared to OAE patients 201 
(90%, 80%, 70% versus 27%, 18% and 0%, respectively). Anti-IFN-lambda1 Ab (IgG or IgM) were 202 
never observed in APS 1 or OAE patients (data not shown). 203 
To evaluate the preservation of relevant antigenic targets after the protein extraction procedure 204 
and to test the quality of pancreatic and adrenal tissues as selected targets in this present work, we first 205 
evaluated the ability of monoclonal IgG antibodies to detect representative antigenic markers of these 206 
tissues. As expected, glutamic acid decarboxylase 65 (GAD 65) and steroid 21 hydroxylase 207 
(21OHase) expression was respectively preserved in pancreatic or adrenal tissues. However, NACHT 208 
leucine-rich-repeat protein 5 (NALP 5) expression was not observed in these 2 tissues, in contrast to 209 
the parathyroid tissue (see Supplemental Figure 1).  210 
To enlarge the spectrum of analysis of T-cell-independent and T-cell-dependent self-reactive 211 
Abs, the reactivity of the 2 isotypes IgM and IgG were respectively evaluated towards adrenal and 212 
pancreatic protein extracts. A similar analysis was preliminarily performed with sera collected in 213 
healthy subjects. As illustrated in Figure1A, each isotype was able to recognize protein bands whose 214 
expression was shared by the 2 tissues (e.g. ~37 kDa for IgG; ~25 kDa for IgM; black arrows). In 215 
addition, each isotype recognized tissue-specific antigens (~50 kDa for IgG in adrenal tissue; ~63-65 216 
kDa for IgM in pancreatic tissue; white arrows in Figure1, A and B). Moreover, a same tissue-specific 217 
antigenic band was recognized by the 2 isotypes (~20 kDa for adrenal tissue; ~60 kDA for pancreatic 218 
tissue; black arrows in Figure1B).  219 
 220 
Serum self-IgG and -IgM reactivities restrictively observed in APS 1 patients 221 
As shown in Figure 2, serum self-IgG and -IgM responses against adrenal and/or pancreas 222 
protein extracts were quantitatively (numbers of bands) and qualitatively (molecular mass of 223 
recognized bands) heterogeneous within subjects, indicating that inter-individual variability occurs. 224 
Firstly, there were more antigenic bands in patients with APS 1 or OAE than in healthy controls. 225 
When we considered all the sera studied, serum self-IgM reactivity was quantitatively greater than 226 
self-IgG reactivity against both extracts, in both groups of patients. For pancreatic extracts, 82 227 
different antigenic bands were identified in self-IgM patterns, while 56 bands were noted in self-IgG 228 
patterns (P<0. 001). Moreover, for adrenal extracts, 71 antigenic bands were identified in self-IgM 229 
patterns, while only 45 bands were noted for self-IgG patterns (P<0. 001). A similar difference was 230 
observed in all groups (APS 1, OAE and healthy subjects). In addition, some antigenic bands detected 231 
either in adrenal or in pancreatic tissues were common in all sera collected (black arrows in Figure2, A 232 
and B).  233 
Marking of antigenic bands related to 21OHase for adrenal extracts and GAD65 for pancreatic 234 
extracts revealed a co-alignment of bands only detectable in some APS 1 and OAE patients and never 235 
detectable in healthy subjects (see Supplemental Table 2). Immune reactivity against 21OHase or 236 
GAD65 was only observed when patients presented adrenal or pancreatic autoimmune diseases. 237 
Compared to classical assays performed in routine to define specific Abs towards theses Ag, western 238 
blotting procedure is less sensitive. In spite of the singularity found in each pattern, variabilities 239 
related to a specific group were observed. Thus, some antigenic bands were only detected on adrenal 240 
and/or on pancreatic extracts in APS 1 patients when IgG and/or IgM isotypes were evaluated. We 241 
then focused statistical analysis (i) on reactivities observed on adrenal tissue in APS 1 and OAE 242 
patients when adrenal insufficiency occurred in these 2 groups, and (ii) on reactivities observed on 243 
pancreatic tissue in APS 1 and OAE patients when pancreatic insufficiency occurred in these 2 groups. 244 
In these 2 situations, specific reactivities towards either adrenal or pancreatic tissues were specifically 245 
observed in APS 1 group. 246 
The presence or absence of protein bands of reactivity was evaluated for each tissue. 247 
Computer-assisted alignment and additional statistical studies allowed us to localize singular IgG 248 
and/or IgM bands of reactivity detected in adrenals (p66, p36 and p25) and in pancreas (p55, p53 and 249 
p22) (thin black arrows in Figure2, A and B). For self-IgG patterns (see Supplemental Figure 2A), the 250 
Chi-square test identified 2 bands unique to adrenal tissue (Ad p36 and Ad p25) and 2 bands unique to 251 
pancreatic tissue (Pc p55 and Pc p53), which were significantly more often recognized by APS 1 252 
patients, compared to OAE patients and healthy controls. For self-IgM patterns (see Supplemental 253 
Figure 2B), the Chi-square test identified 2 bands unique to adrenal tissue (Ad p66 and Ad p25) and 2 254 
bands unique to pancreatic tissue (Pc p53 and Pc p22), which were significantly more often recognized 255 
by APS 1patients compared to the other two groups. Thus two protein bands (Ad p25 and Pc p53) 256 
were recognized both by IgG and IgM.  257 
 258 
Characterization of discriminant antigenic bands of reactivity 259 
To further characterize the discriminant bands of reactivity, we used a serological proteomic 260 
approach. Identification of antigenic targets of such reactivities was first performed by comparing 1-D 261 
and 2-D immune patterns. Sera were used to identify antigenic candidates on a proteomic map 262 
obtained after 2-D electrophoresis performed for each tissue. Two-dimensional electrophoresis 263 
followed by immunoblotting revealed the presence of multiple antigenic spots for pancreatic (Figure3) 264 
and adrenal protein extracts (Figure4). Then, superimposition of antigenic spots and protein spots 265 
revealed by a standard colloidal Coomassie blue-stained two-dimensional gel electrophoresis enabled 266 
us to select proteins for further in-gel digestion and MALDI-TOF/TOFanalysis on the basis of peptide 267 
mass matching (19).  268 
This approach enabled us to identify some proteins as potent discriminant antigens for each 269 
tissue using the SWISS-PROT database (Table 2). The antigens identified in our study were either 270 
tissue-specific or ubiquitous proteins. Some antigens were targeted both by self-reactive IgM and IgG 271 
reactivities: one for adrenal tissue, and 2 for pancreatic tissue. As shown in (Figure 3 and Table 2), 272 
pancreatic (Pc) p55 was characterized as pancreatic α-amylase (P04746), Pc p53 as pancreatic 273 
triacylglycerol lipase (P16233), and Pc p22 as pancreatic regenerating protein 1 (P05451). 274 
Furthermore, adrenal (Ad) p66 was characterized as heat shock cognate 71-kDa protein (P11142), Ad 275 
p36 as aldose reductase (P15121) and Ad p25 as peroxiredoxin-2 (P32119) (Figure 4 and Table 2). 276 
 277 
Evaluation of discriminant reactivities observed in APS 1 patients against targeted recombinant 278 
proteins 279 
In order to strengthen the data observed on tissue-extracted proteins, we performed 1-D blotting with 280 
recombinant proteins identified by the 2-D approach. Both IgG and IgM reactivities were tested in all 281 
APS 1 sera against the 6 discriminant antigens.  282 
For the IgG isotype, and except for lipase, the autoreactivity frequency was similar between tissue 283 
protein extracts and recombinant proteins (Table 3). Moreover, in terms of presence or absence of 284 
reactivity, concordance levels were higher than 80% when IgG reactivities were evaluated either on 285 
tissue extract or recombinant proteins. For the IgM isotype, whatever the frequencies observed, the 286 
concordance in terms of presence or absence of reactivity was lower than 75% (Table 3).  287 
 288 
Discussion 289 
In previous studies, specific serum autoAbs were usually investigated by techniques using 290 
purified self-Ags and/or relevant peptides from preselected targets (20). We previously demonstrated 291 
the value of using a large panel of antigens derived from different tissue extracts to analyze the serum 292 
autoAb repertoire in organ-specific autoimmune disease (13, 15). Using this approach, we illustrated 293 
that the specific antibody response associated with a pathological condition could be rich and diverse 294 
and not only focalized on a restricted set of antigenic targets. Among the different reactivities, some of 295 
them could constitute a specific pathological signature of the disease. In this study, we aimed to 296 
analyze the diversity of the autoantibody repertoire in APS 1, not for diagnostic purposes, but to 297 
appreciate potential biases specifically associated with this condition. APS 1 is classically described as 298 
an Aire-mediated T-dependent disease. In this view, we performed a specific analysis of both the IgG- 299 
and IgM-specific auto-antibody repertoires in APS 1 patients versus controls, to evaluate the specific 300 
distortion restricted to the IgG repertoire in this disease, whereas the IgM patterns were attempted not 301 
to be changed.  302 
We have first evaluated anti-cytokine Ab reactivity in order to assess whether our patients are 303 
representative of both APS 1 and OAE patients reported elsewhere (12). We chose then to analyze the 304 
autoAb repertoire on both adrenal and pancreatic protein extracts based on the large diversity of 305 
autoAb specificities observed in the sera of APS 1 patients and controls in these tissues. Other tissue 306 
protein extracts have been evaluated (gastric, ovarian, testis, liver, thyroid, parathyroid, skin) (not 307 
shown) and reveals less global reactivity or more homogeneous autoreactive patterns between groups 308 
of patients, as observed previously (10). Moreover, adrenal and pancreatic tissue protein extracts 309 
contained specific antigens which have been described as being targeted by autoAb associated with 310 
clinical manifestations reported in APS 1 and other autoimmune endocrinopathies, such 21OHase and 311 
GAD 65. We have confirmed that, using monoclonal Abs with our western blotting procedure, we 312 
could reveal these specificities in these tissues when Abs were present in serum of individuals. As 313 
expected, we did not reveal NALP5 expression in these 2 tissues, whereas it was observed in the 314 
parathyroid protein extract. Thus, we could not detect anti-NALP5 autoAbs in this study. 315 
We first evaluated the global richness of the immune repertoire. With regard to the IgM 316 
autoAb panels, we observed in all individuals a more diversified repertoire than with IgG, which could 317 
be related to the natural immune repertoire (‘immunculus’) that has been described as being largely 318 
composed of IgM autoAbs (21). By contrast, we observed a more diversified IgG autoAb repertoire in 319 
patients suffering from autoimmune diseases, namely APS 1 and OAE, than in healthy subjects. This 320 
phenomenon could be related to at least two events. First, a specific defect of the educational process 321 
of the immune system leading to the persistence of autoreactive immune cells could contribute to the 322 
enlargement of this autoreactiveAb repertoire in patients. Secondly, the tissue damage associated with 323 
the autoimmune process could contribute to enlarging the panel of autoantigens that are expressed in 324 
altered tissues and presented to these immune cells. This phenomenon may itself contribute both to the 325 
preservation of autoimmune specificities and to the emergence of new autoreactiveAb specificities, 326 
generating a neo-repertoire. These two processes may also act by a summation effect.  327 
In a second step, we analyzed the intra-individual variations of the autoreactive patterns 328 
between adrenal and pancreatic tissues. We observed that some IgM or IgG reactivities were co-329 
aligned between the two tissues, suggesting that a cluster of widely distributed auto-antigens could be 330 
targeted by these reactivities. By contrast, some bands of reactivity were exclusively observed on 331 
either the adrenal or the pancreatic protein extracts, suggesting tissue-specific autoimmune targeting. 332 
We next studied the inter-individual variations of the autoreactive patterns independently on the 333 
adrenal or pancreatic tissues. Whereas we did not observe any difference in terms of number of bands 334 
of reactivity between APS 1 and OAE, we hypothesized that qualitative distortions could be 335 
specifically associated with the Aire-related pathological process in APS 1. This condition is described 336 
as a T-dependent autoimmune disorder which preferentially impacts the IgG autoAb repertoire. 337 
Surprisingly, in APS 1 patients compared to the 2 control groups, our approach demonstrated as much 338 
as specific distortions in IgM repertoire that in IgG repertoire. In our study, some IgM specificities 339 
were shared by different APS 1 patients, suggesting that the autoreactivities supported by this isotype 340 
are sustainable and not transitory reactivity brought to switch to the IgG class. Several studies have 341 
reported an extrathymic expression of Aire that influenced the T-cell repertoire(3, 5). Our data suggest 342 
that Aire expression deficiency in peripheral lymphoid organs could also impact the autoreactive IgM 343 
repertoire. Sustained IgM production by B cells has been associated with two different B-cell 344 
subpopulations in humans. It has been reported that during germinal center differentiation, follicular B 345 
cells could maturate into long-lasting IgM-expressing memory B cells through T-dependent 346 
mechanisms (22). By contrast, T-independent mechanisms generate marginal zone B cells which 347 
produce IgM in response to non-peptidic epitopes (23, 24). Interestingly, numerous studies have 348 
focused on changes affecting B-cell homeostasis and T-cell-independent marginal zone (MZ) B-cell 349 
subsets in Aire
-/-
 mice (25–28). In addition, recent studies have underlined the fact that Aire can 350 
regulate T-cell-independent B-cell responses through B-cell-activating factor of the TNF family 351 
(BAFF) (28).  352 
 Using a serological proteomic approach, we did not observe any discriminant reactivities 353 
towards 21OHase or GAD specifically associated with APS 1 condition. These results could be related 354 
to the presence of common reactivities in the control group of patients with other autoimmune 355 
endocrinopathies, since both antibodies could be observed in both APS 1 and other 356 
polyendocrinopathies. By contrast, we noted that some reactivity were statistically more observed in 357 
the APS 1 group. They targeted tissue-specific antigens such as amylase, lipase and pancreatic 358 
regenerating protein 1 alpha. They also recognized three ubiquitous antigens: peroxyredoxine-2, heat 359 
shock cognate 71-kDa protein and aldose reductase. The discriminant recognition of amylase, lipase 360 
and pancreatic regenerating protein 1 alpha emphasizes pancreatic exocrine dysfunctions widely 361 
evoked either in APS 1 patients who could develop malabsorption caused by several mechanisms such 362 
as exocrine pancreatic insufficiency (29–35) or in experimental models such as NOD Aire-deficient 363 
mice (5, 36).  364 
The discriminant targeting of aldose reductase, a ubiquitous protein mainly expressed in 365 
adrenal glands (37), by IgG Abs in APS 1 patients, requires consideration. It has been shown that the 366 
expression of aldose reductase is regulated by Aire in mTECs in mice (5). In addition, the Aire-367 
dependent expression of other ubiquitous Ags has also been described in eTACs localized in lymph 368 
nodes and the spleen (3). Multi-organ inflammation in Aire-deficient models is also known to be 369 
associated with the presence of serum autoAbs against proteins specifically produced by these organs. 370 
In our study, the discriminant targeting of some ubiquitous antigens, such as peroxyredoxine-2 and 371 
heat shock cognate 71-kDa protein, could be indicative of endogenous danger signals involving 372 
cellular oxidative stress. It can be compared to biomarkers previously described in systemic 373 
autoimmune disorders (38, 39). 374 
In parallel with the combination of reactivities classically associated with APS 1 diagnosis, 375 
our data highlight some biomarkers that could be associated with a particular tissue alteration 376 
(exocrine pancreatic-specific antigens) or more general pathological processes associated with 377 
autoimmune diseases. We aimed to design an in vitro assay to evaluate the presence of these 378 
reactivities, using recombinant antigens. IgG reactivities towards amylase, aldose reductase and 379 
peroxyredoxine-2 were also observed in APS 1 patients when we used recombinant proteins as targets. 380 
By contrast, IgM reactivities against HSP71, REG-1A, and lipase were not concordantly observed 381 
between tissue extracts and recombinant proteins. When detected, such IgM reactivities were 382 
systematically observed at a lower frequency when we used recombinant proteins. Such a discrepancy 383 
between the immunoproteomic approach and an in vitro assay using recombinant targets has 384 
previously been observed (40). To avoid the impact of folding on antigenic recognition, we chose to 385 
use the same one-dimensional electrophoresis experimental procedure. The denaturing conditions lead 386 
to the linearization of proteins whatever their origin: tissue extracts or purified wheat germ 387 
recombinant proteins. Nevertheless, the presence of post transcriptional modifications (PTMs), such as 388 
glycosylation, on the targeted antigens could support these observations. Eukaryotic PTMs are not 389 
observed in the wheat germ expression system, so that specific modifications of native proteins are not 390 
present on the recombinant protein. Interestingly, we observed a major reactivity discrepancy when we 391 
focused on the IgM isotype. Once again, these observations could highlight the impact of the thymo-392 
independent processes associated with the dynamic changes in the IgM repertoire in APS 1 patients. 393 
Conventional immunoassays are usually performed with limited antigenic targets, the choice 394 
of which has been driven by a supposedly well-known physiopathogenic rationale. Advances in 395 
proteomic methodologies (in vitro gene expression, 2-DE and mass spectrometry) have allowed the 396 
emergence of broad spectrum analysis methods. These approaches have been developed to overcome 397 
the limits of conventional methods. Based on a “without any a priori” strategy, they offer a 398 
simultaneous analysis of a large spectrum of reactivities, which surpasses the physiopathogenic 399 
hypotheses and offers an integrative interpretation of results. When applied to the APS 1 condition, 400 
this immunoproteomic methodology not only reveals the expected IgG repertoire biases, it also 401 
identifies IgM repertoire distortions. The latter alterations could be partially associated with T-402 
independent immunological events related to the impact of post-translational modifications of 403 
antigens. Our results highlight the fact that AIRE also impacts the presentation of thymo-independent 404 
antigens. It points out that autoimmune alterations observed in APS 1 are not only related to Aire-405 
driven T-cell clonal deletion deficiency. At an individual level, this approach highlighted original 406 
antigenic targets, potentially associated with tissue injury and cellular dysfunctions related to the 407 
singular clinical evolution in each patient.  408 
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Table 1.Main Clinical Characteristics of APS 1 and OAE patients.AIRE gene mutations are detailed in APS 1 patients. 
 
 
Patient 
Age 
(Gender) 
AIRE gene mutations Clinical manifestations 
Autoantibodies 
TPO TG TBII GAD IA2 21 OHase GPC tTg  
APS 1            
1 37 (F) c.967_979del13 / c.967_979del13 HPT, AI, DM, OI, PA, C, A, K    + + + +  
2 28 (M) c.1193delC / c.1193delC HPT, AI, PA, C, M + +    +   
3* 42 (F) c. 1097 C>T / c. 769 C>T HPT, AI, OI, PA, C         
4 52 (M) c.769C>T/c.967_979del13 HPT, AI, C, A, K +        
5** 31 (F) c.967_979del13 / c.967_979del13 HPT, AI, OI, PA, C, A      +   
6** 26 (M) c.967_979del13/ c.967_979del13 C, A, K         
7 25 (M) c.966_978del13 / c.967_979del13 HPT, AI, C, A      +   
8 23 (M) c.967_979del13 / c.967_979del13 AI, DM, C, A,M    +     
9 51 (M) c.769C>T/c.14-1-28G>C HPT, AI, M, C    +  +   
10 15 (M) c.967_979del13 / c.967_979del13 AI, C, A, M    +     
11 9 (M) c.769C>T/c.967_979del13 AI, C, A      +   
12 32 (M) c.967_979del13/ c.967_979del13 HPT, AI, T, A, K, C + +  +  +   
13 39 (F) c.967_979del13 / c.967_979del13 AI, OI, C  +       
14* 57 (F) c. 1097 C>T / c. 769 C>T HPT  +       
OAE            
15 25 (F) ND T, OI + +       
16 25 (F) ND DM, PA, M    + +   + 
17 60 (M) ND HPT, T, PA + +     +  
18 62 (F) ND T, OI, PA + +     +  
19 57 (F) ND DM, T, PA + +  +   +  
20 74 (F) ND AI, DM, T + +    +   
21 56 (F) ND DM, T, M + +  + +   + 
22 23 (F) ND T +        
23 63 (M) ND AI, DM, T + +    +   
24 47 (F) ND AI, T + + +   +   
25 43 (F) ND AI, DM, T + + +      
26 54 (F) ND AI, T + +    +   
27 48 (M) ND DM, M         
28 35 (F) ND T + + +      
29 61 (M) ND T, PA + + +    +  
30*** 39 (M) ND AI      +   
31*** 37 (M) ND AI         
 Clinical manifestations: HPT: Hypoparathyroidism; AI: Adrenal insufficiency; DM: Diabetes mellitus; T: Thyroiditis; OI: Ovarian insufficiency; PA: Pernicious anemia; 
M: Malabsorption; K : Keratitis; A: Alopecia; C: Candidiasis.  
Specific Antibodies: TPO: anti-thyroperoxidase; TG: anti-thyroglobulin; TBII: thyroid-binding inhibitory immunoglobulin; GAD : anti-glutamic acid decarboxylase 65 
(GAD 65) ; IA2: antityrosine phosphatase; 21 OHase : anti-steroid 21 hydroxylase ; GPC: anti-gastric parietal cells; tTg: anti-tissular Transglutaminase  
 
M = male, F = female; ND = not done; * siblings, ** siblings, *** siblings. 
  
Table 2. Characterization of Discriminant Antigens by MS and MS/MS. Antigens Preferentially Recognized by APS 1 Patients (Chi-2 test results). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Name of 
antigenic 
band 
Isotype 
concerned 
UniProtKB/ 
Swiss-Prot 
references 
Name 
Theoretical mass 
(Observed mass) (kDa) 
Theoretical IP 
(Observed IP) 
MS 
Mascot 
Score  
MS 
Sequence 
coverage 
MS/MS 
Mascot 
Score  
MS/MS 
Sequence 
coverage 
ADRENAL TISSUE         
Ad p66 IgM P11142 
Heat shock cognate 71-kDa 
protein 
70.7 (66) 5.4 (5.3-5.5) 169 33.3 217;8 6.32 
Ad p36 IgG P15121 Aldose reductase 35.7 (36) 6.6 (6.1-6.9) 191 50.2 132.7 12.69 
Ad p25 IgM/IgG P32119 Peroxiredoxin-2 21.7 (25) 5.6 (5.6) 190 53.3 537.8 33.5 
PANCREATIC TISSUE         
Pc p55 IgG P04746 Pancreatic α-amylase 57.7 (55) 6.7 (7.1) 201 45.6 338 2.77 
Pc p53 IgM/IgG P16233 
Pancreatic triacylglycerol 
lipase 
49.5 (53) 6.2 (7.0) 187 68.9 561.7 16.7 
Pc p22 IgM P05451 
Pancreatic regenerating 
protein 1 alpha 
18.7 (22) 5.6 (5.5) 120 54 365.5 30.7 
Table 3. Level of Concordance of Autoreactivity According to the Origin of the Antigens (Tissue or Recombinant) and to the Isotype (IgG or IgM) 
 
    Autoreactivity frequency   Concordance level 
Target Isotype 
in 
tissue 
on recombinant 
 protein 
  
Presence of 
reactivity 
Absence of  
reactivity 
Adrenal tissue             
Heat shock cognate 71-kDa protein IgM 50% 50%   60% 40% 
Aldose reductase IgG 40% 50%   100% 85% 
Peroxiredoxine-2 
IgG 50% 60%   100% 80% 
IgM 40% 40%   75% 85% 
Pancreatic tissue             
Pancreatic alpha-amylase IgG 100% 90%   90% - 
Pancreatic triacylglycerol lipase 
IgG 100% 40%   40% - 
IgM 50% 30%   30% 71% 
Pancreatic regenerating protein 1 alpha IgM 50% 0%   0% 100% 
 
  
Supplemental table 1. Frequency of detection of IgG and IgM anti-IFN-alpha2A, anti-IFN –omega, anti-IL-22, anti-IL-17A and anti-IL-17F antibodies in APS 1 and 
OAE patients  
 
 IFN-alpha2A IFN –omega IL-22 IL-17A IL-17F 
 
IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM 
APS 1 patients 90% 0% 40% 0% 80% 0% 0% 0% 70% 0% 
OAE patients 27% 0% 0% 0% 18% 0% 0% 0% 0% 0% 
 
  
Supplemental table 2.Frequency of detection of a co-alignment with anti 21 OHase and anti GAD65 IgG monoclonal antibodies in APS 1 patients, OAE patients and 
healthy controls. 
 
 
GAD65  21OHase 
 
IgG IgM  IgG IgM 
APS 1 patients 33% 25%  60% 0% 
OAE patients 40% 26%  46% 0% 
Healthy controls 0% 0%  0% 0% 
 
 
 
 
